Equillium to present translational data on itolizumab for acute graft-versus-host disease at 61st american society of hematology annual meeting and exposition

Equillium, inc. announced that data supporting the role of the cd6-alcam pathway as a relevant target for patients with acute graft-versus-host disease (agvhd) along with details of the equate phase 1b/2 trial design will be presented at the 61st american society of hematology (ash) annual meeting and exposition being held from december 7-10, 2019 in orlando, florida. data demonstrating itolizumab efficiently inhibits t cell responses in samples taken from patients with agvhd received the ash abstract achievement award. additionally, data supporting itolizumab as a potential systemic treatment that can modulate pathogenic t effector cell activity in an in vivo model of disease has been published online-only in blood, the journal of ash.'today, approximately 30-70% of patients receiving allogeneic hematopoietic stem cell transplant (hsct) with standard gvhd prophylaxis regimens are diagnosed with agvhd, a multisystem disorder that occurs when the transplanted immune system attacks host tissues.
EQ Ratings Summary
EQ Quant Ranking